Which act created the biosimilar pathway and outlines regulatory approval for biosimilars?

• A. Biologics Price Competition and Innovation Act (BPCIA)
• B. Health Care and Education Reconciliation Act
• C. FDA Modernization Act
• D. Drug Price Competition and Patent Term Restoration Act

Answer: (A)

The act creating a biosimilar regulatory pathway is designed to bring competition to biologic medicines while ensuring safety and efficacy through a rigorous, but streamlined, approval route. It established an abbreviated licensure process for products that are highly similar to an already approved biologic (the reference product). The key idea is that sponsors can rely on comparative data to show biosimilarity rather than repeating the full development program required for a new biologic. If the sponsor demonstrates high similarity and no meaningful differences in safety, purity, and potency, FDA can approve the biosimilar; an additional designation of interchangeability may be granted, allowing pharmacy-level substitutions in appropriate settings. The act also provides data exclusivity protections for the reference biologic and lays out procedural elements for patent disputes and the exchange of information between sponsors, all aimed at balancing innovation incentives with broader patient access.